Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in ...
Learn how a strategic preclinical toxicology plan can reduce risk, save time, and accelerate drug development. Request your free white paper now to discover best practices for study design, dose ...
Perceptive Discovery, a leading preclinical CRO supporting radiopharmaceutical and oncology drug development, and Certis ...
As Chief Scientific Officer, Dr. Bell will lead Genovyn’s scientific strategy, AI platform development, scientific integration, discovery enablement, and portfolio prioritization. He will oversee ...
Antibody-drug conjugates (ADCs) hold great promise as targeted cancer therapeutics. But their complex structure poses significant development and safety challenges for biopharma. In this GEN webinar, ...
TORONTO and HAIFA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a preclinical-stage biotechnology company ...
Conexeu Sciences Inc. (Nasdaq: CNXU) ("Conexeu" or the "Company"), a biotechnology company advancing tissue regeneration, today announced the launch of a preclinical development program for B.R.E.A.S.
Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...
In a recently published study, researchers from Northeast Agricultural University and Jiangsu Kanion Pharmaceutical Co. Ltd. aimed to improve the oncolytic effect of existing Newcastle disease virus ...
Molecular Partners AG and Orano Med have announced the development of MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) for ovarian cancer treatment, which shows promising tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results